EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Combined type 2 cytokine blockade enhances PD-1-mediated antitumor immunity

Thomas Fabre, Eleanore Hendrickson, Katherine McGourty, Paola M Marcovecchio, James McMahon, Sara Patti, KaiLi Cage, Stephen Searles, Christella Widjaja, Christopher Stairiker, Kathryn Bound, Roxanne Martino und 10 weitere

Cell Reports · 2026

DOI: 10.1016/j.celrep.2026.117910 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Reports, 2026. Verfasst von Thomas Fabre und 21 weiteren Autor:innen. Beteiligte Einrichtung: Inflammation & Immunology Research Unit, Pfizer Inc., 1 Portland St., Cambridge, MA 02139, USA. Hauptthemen laut MEDLINE: Programmed Cell Death 1 Receptor, Cytokines, Neoplasms. Die Arbeit nennt 106 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Programmed Cell Death 1 ReceptorCytokinesNeoplasmsAnimalsHumansDendritic CellsMiceCell Line, TumorThymic Stromal LymphopoietinInterleukin-4FemaleInterleukin-13Immune Checkpoint InhibitorsMice, Inbred C57BL

Stichwörter der Autor:innen

CD8 T cellsCP: cancerCP: immunologycheckpoint inhibitorsdendritic cellstype 2 immunity

Substanzen

Programmed Cell Death 1 ReceptorCytokinesThymic Stromal LymphopoietinInterleukin-4Interleukin-13Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Inflammation & Immunology Research Unit, Pfizer Inc., 1 Portland St., Cambridge, MA 02139, USA.
  • Oncology Research Division, Pfizer Inc., 10555 Science Center Dr., San Diego, CA 92121, USA.
  • Biomedicine Design, Pfizer Inc., 10555 Science Center Dr., San Diego, CA 92121, USA.
  • Biomedicine Design, Pfizer Inc., 1 Portland St., Cambridge, MA 02139, USA.
  • Inflammation & Immunology Research Unit, Pfizer Inc., 1 Portland St., Cambridge, MA 02139, USA. Electronic address: alex.m.barron@gmail.com.
  • Inflammation & Immunology Research Unit, Pfizer Inc., 1 Portland St., Cambridge, MA 02139, USA. Electronic address: richard.gieseckiii@pfizer.com.

Zitieren

APA

Fabre, T., Hendrickson, E., McGourty, K., Marcovecchio, P. M., McMahon, J., Patti, S., Cage, K., Searles, S., Widjaja, C., Stairiker, C., Bound, K., Martino, R., Pyszczynski, E., Zhang, Y., Thomas, G., Stoner, S. A., Ching, K. A., Jin, F., Dillon, C. P., …, & Gieseck, R. L. (2026). Combined type 2 cytokine blockade enhances PD-1-mediated antitumor immunity. Cell Reports. https://doi.org/10.1016/j.celrep.2026.117910

Vancouver

Fabre T, Hendrickson E, McGourty K, Marcovecchio PM, McMahon J, Patti S, et al. Combined type 2 cytokine blockade enhances PD-1-mediated antitumor immunity. Cell Reports. 2026. doi:10.1016/j.celrep.2026.117910

BibTeX
@article{Fabre2026,
  author = {Fabre, Thomas and Hendrickson, Eleanore and McGourty, Katherine and Marcovecchio, Paola M and McMahon, James and Patti, Sara and Cage, KaiLi and Searles, Stephen and Widjaja, Christella and Stairiker, Christopher and Bound, Kathryn and Martino, Roxanne and Pyszczynski, Edward and Zhang, Ying and Thomas, Graham and Stoner, Samuel A and Ching, Keith A and Jin, Fang and Dillon, Christopher P and Wynn, Thomas A and Barron, Alexander M S and Gieseck, Richard L},
  title = {Combined type 2 cytokine blockade enhances PD-1-mediated antitumor immunity},
  journal = {Cell Reports},
  year = {2026},
  doi = {10.1016/j.celrep.2026.117910}
}
Kostenlos starten →